LifeStance Q4 revenue $325.5M (+16% YoY); 2025 EBITDA guidance $130-150M

LifeStance Health Group, Inc.

Q4 revenue $325.5M (+16% YoY); full year $1.251B (+19% YoY).
Net loss narrowed to $7.1M in Q4 vs $45.0M prior; full year $57.4M vs $186.3M.
Adjusted EBITDA Q4 $32.8M (+62% YoY); full year $119.7M (+103% YoY).
2025 guidance: revenue $1.40B-$1.44B, Center Margin $440M-$464M, Adj. EBITDA $130M-$150M.
Free cash flow $85.7M for 2024; cash $154.6M, net long-term debt $279.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.